Slide 1: Aroa Biosurgery (ARX) – MASTRR Interim Analysis
rsonal use only Aroa Biosurgery (ARX) – MASTRR Interim Analysis UNLOCKING REGENERATIVE HEALING FOR EVERY BODY 1
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation (07 Oct 2026) has been prepared by Aroa Biosurgery Limited, New Zealand company number 1980577, ARBN 638 867 473. This presentation: rsonal use only • Is for information purposes only and does not contain all information relevant or necessary for an
Slide 3: Contents
CONTENTS rsonal use only 01 Introduction 02 Overview 03 Interim analysis 04 What this means 05 Q&A 3
Slide 4: Introduction
Introduction Bioscaffolds have an established history of use rsonal use only But • Dearth of high quality large scale data • Limited clinical evidence for specific product use in a wide range of procedures & patients • Unmet clinical needs • Opportunity to provide more robust evidence • Mixed view o
Slide 5: Chief Scientific Officer Barnaby C. H. May, Ph.D.
rsonal use only CHIEF SCIENTIFIC OFFICER Barnaby C. H. May, Ph.D. 5 | Confidential. Not for distribution.
Slide 6: Myriad Augmented Soft Tissue Reconstruction Registry (MASTRR)
TM Myriad Augmented Soft Tissue Reconstruction Registry (MASTRR) A Registry of prospective Myriad data rsonal use only Goals: • Demonstrate safety and efficacy of Myriad Matrix and Myriad Morcells across a range of soft tissue reconstruction procedures • Utilize a prospective single arm registry stu
Slide 7: Prospective Data in Soft Tissue Reconstruction
Prospective Data in Soft Tissue Reconstruction Advantages of a Registry Study design Feature Registry Study Traditional RCT rsonal use only Evaluate real-world safety, performance, Determine comparative efficacy/effectiveness Primary purpose utilization, and outcomes between predefined interventions
Slide 8: MASTRR Registry sites and enrolment
MASTRR Registry 12/15 Sites 550/800 Current metrics Subjects Univ. of Iowa Froedtert (Milwaukee) OSU (Columbus) rsonal use only Site Focus Area: Trauma/Burn Nuvance (Poughkipsee) Colorectal Tower Health (Reading) Lower Extremity Lancaster Hospital (PA) Lifebridge (Baltimore) Northeast Georgia (Gaine
Slide 9: MASTRR Registry Research Outputs
MASTRR Registry Research Outputs rsonal use only Lawlor et al Trinh et al 1 Complex lower extremity reconstruction 5 Pressure injury reconstruction Cormican et al Kennedy et al 2 Trauma and acute care 6 Partial thickness burns Nasseri et al Short et al 3 Comparative pilonidal sinus 7 Interim safety
Slide 10: MASTRR Prospective Registry Outputs
MASTRR Prospective Registry Outputs rsonal use only Limb 3 Flap Burns 2 Trauma salvage 1 Closure 4 • n=32 deep partial • n=46 OFM implant • n=130 complex lower • n=61 trauma and thickness burns beneath local tissue extremity ACS defects flaps for pilonidal reconstruction • Median 107cm2 • Median 22.
Slide 11: Study Chair – MASTRR Registry Dr. Tracee Short
rsonal use only STUDY CHAIR – MASTRR REGISTRY Dr. Tracee Short 11
Slide 12: Safety of Ovine Forestomach Matrix Across Soft Tissue Defects
rsonal use only Safety of Ovine Forestomach Matrix Across 474 Soft Tissue Defects: Interim Results from the Prospective Multicenter MASTRR Registry Short T, Lawlor J, Martyka P, Wolf JH, Felton JM, Smith AA, Nasseri YY, Barnajian M, Vassy WM, Cormican M, Kumar P, Choi JJ, Lau L, Loftus JH, | For edu
Slide 13: Subject and defect level populations
Short et al. 2025 | MASTRR Registry Interim Safety Analysis Subject and defect level populations rsonal use only 35.8 30.4 91.5 411 10 28.3 % % % Subjects Sites Median BMI Diabetic Vascular ASA Grade Disease II or higher 59.8 88.6 11.4 15.0 474 24.0 % % % % | For educational purposes only Defects >1
Slide 14: Clinical utility: A broad range of surgical applications
Short et al. 2025 | MASTRR Registry Interim Safety Analysis Clinical utility: A broad range of surgical applications Broad range of surgical procedures from trauma and acute care, colorectal and burns rsonal use only 65.2 9.7 25.1 1 % % % Median product Dermal Fistula Implantation application recons
Slide 15: Standardized adverse event reporting
Short et al. 2025 | MASTRR Registry Interim Safety Analysis Standardized adverse event reporting • If a subject is enrolled in a clinical study ANY Severity rsonal use only adverse event related or unrelated to the intervention must be reported within the study 1=mild 2=moderate • Structured and sta
Slide 16: Safety outcomes
Short et al. 2025 | MASTRR Registry Interim Safety Analysis Safety outcomes rsonal use only Zero 1 Definitively device- Probable device related AEs related AEs 27.1 | For educational purposes only Median follow-up period (weeks) 16
Slide 17: Safety outcomes
TS Short et al. 2025 | MASTRR Registry Interim Safety Analysis Safety outcomes rsonal use only 8.0 11.9 32.1 % % % Index defect Non-index defect Incidental AE’s related AEs related AE’s 0.7 2.9 0.0 % % % | For educational purposes only Deep tissue Superficial Graft loss infection infection 17
Slide 18: Safety outcomes
Short et al. 2025 | MASTRR Registry Interim Safety Analysis Safety outcomes rsonal use only | For educational purposes only 18
Slide 19: Comparative outcomes: deep tissue infection rate
Short et al. 2025 | MASTRR Registry Interim Safety Analysis Comparative outcomes How does the deep tissue infection rate for Myriad compare? rsonal use only Reported deep Product Reference Study type Defect type Sample size tissue infection rate Short T. et al. Adv in Myriad Prospective registry Var
Slide 20: Questions & Answers
rsonal use only AROA BIOSURGERY Questions & Answers 20
Slide 21: What this means
What this means As the largest prospective evidence base in this category, the rsonal use only MASTRR registry is becoming a commercial asset How • Surgeon confidence (in contaminated and complex cases) • Unlocks the conservative/sceptical early majority • Competitive differentiation • Supports case
Slide 22: Questions & Answers
rsonal use only AROA BIOSURGERY Questions & Answers 22
Slide 23: Thank you for attending
Thank you rsonal use only for attending investor@aroa.com Visit www.aroa.com www.linkedin.com/company /aroa-biosurgery-limited/ 64 Richard Pearse Drive, Auckland 2022, New Zealand PO Box 107111, Auckland Airport, Auckland 2150, New Zealand 23